Scarica l'app Stockscreener
2.20
1.85%
0.04
Precedente Chiudi:
$2.16
Aprire:
$2.13
Volume 24 ore:
1.40M
Relative Volume:
0.57
Capitalizzazione di mercato:
$332.26M
Reddito:
$7.25M
Utile/perdita netta:
$-17.41M
Rapporto P/E:
-8.3746
EPS:
-0.2627
Flusso di cassa netto:
$-38.33M
1 W Prestazione:
-10.57%
1M Prestazione:
+32.53%
6M Prestazione:
+34.15%
1 anno Prestazione:
+547.06%
Intervallo 1D:
$2.08
$2.215
Intervallo di 1 settimana:
$2.02
$2.45
Portata 52W:
$0.2425
$2.72
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.20 | 332.26M | 7.25M | -17.41M | -38.33M | -0.2627 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Iniziato | Roth Capital | Buy |
| 2025-11-17 | Iniziato | Leerink Partners | Outperform |
| 2025-10-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-08 | Ripresa | B. Riley Securities | Buy |
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
OVID.O Technical Analysis & Stock Price Forecast - Intellectia AI
OVID.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
OVID Should I Buy - Intellectia AI
OVID News & Events - intellectia.ai
IPO Launch: Does Ovid Therapeutics Inc have declining or rising EPSWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn
Gains Report: Can Ovid Therapeutics Inc maintain its current growth rate2026 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Ovid Therapeutics (OVID) price target increased by 14.29% to 4.87 - MSN
Rate Hike: Is Ovid Therapeutics Inc still a buy after recent gains2026 Chart Watch & High Accuracy Trade Alerts - baoquankhu1.vn
OVID Therapeutics Inc (NASDAQ:OVID) Passes Minervini's High-Growth Momentum and Trend Template Filters - ChartMill
Aug Reactions: How does Ovid Therapeutics Inc score in quality rankingsCEO Change & Weekly Stock Performance Updates - baoquankhu1.vn
Aug Big Picture: Does Ovid Therapeutics Inc have declining or rising EPSBuy Signal & Weekly Momentum Stock Picks - baoquankhu1.vn
Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Ovid spikes as Wedbush moves to Outperform on lead asset - MSN
Lifesci Capital Has Negative Estimate for OVID Q1 Earnings - MarketBeat
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Ovid Therapeutics (NASDAQ: OVID) chair exercises 47,333-share warrant at $1.40 - Stock Titan
Investors pour $60M into Ovid Therapeutics to advance seizure drugs - Crain's New York Business
Ovid Therapeutics' new epilepsy trial data ignites rally - MSN
Ovid Therapeutics secures $60M funding to advance epilepsy drug programs - MSN
If You Invested $1,000 in Ovid Therapeutics Inc (OVID) - Stock Titan
Here's why Ovid Therapeutics stock popped higher today - MSN
Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to Hold - MarketBeat
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma - MSN
Ovid Therapeutics Stock Surges on Positive Drug Trial Data and Financing Plans - StocksToTrade
Ovid Shares Surge with Positive Phase 1 Results and Strategic Moves - timothysykes.com
Wedbush Forecasts Strong Price Appreciation for Ovid Therapeutics (NASDAQ:OVID) Stock - MarketBeat
Ovid Therapeutics (OVID) Sees Price Target Raised by Wedbush | O - gurufocus.com
Bond Watch: How does Ovid Therapeutics Inc score in quality rankingsMarket Performance Report & Daily Technical Forecast Reports - baoquankhu1.vn
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding - Seeking Alpha
Here's Why Ovid Therapeutics Stock Popped Higher Today - AOL.com
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com
Leerink reiterates Ovid Therapeutics stock rating on safety data By Investing.com - in.investing.com
Ovid Therapeutics Hits New 52-Week High of $2.50, Marking Major Milestone - Markets Mojo
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally - Sahm
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results - Sahm
Leerink reiterates Ovid Therapeutics stock rating on safety data - Investing.com
Ovid Therapeutics advances OV329 epilepsy drug, secures $60M financing - MSN
Ovid’s KCC2 direct activator OV-4071 cleared for clinic - BioWorld MedTech
Ovid Therapeutics (OVID) Q4 earnings and revenues surpass estimates - MSN
Ovid Therapeutics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:OVID) 2026-03-19 - Seeking Alpha
Ovid Therapeutics Shares Surge After Positive Epilepsy Drug Trial Results - MSN
Ovid Therapeutics raises $60 million to expand drug development By Investing.com - Investing.com South Africa
Ovid Therapeutics raises $60M, expands epilepsy drug development By Investing.com - Investing.com South Africa
Ovid Therapeutics: Advancing Small Molecule Medicines for Epilepsy and Psychiatric Disorders – Pipeline, Strategy, and Company Overview - Minichart
Ovid Therapeutics (OVID) Q4 Profit Challenges Ongoing Loss Narrative - simplywall.st
Earnings Call Summary | Ovid Therapeutics(OVID.US) Q4 2025 Earnings Conference - 富途牛牛
Ovid Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Ovid Therapeutics Q4 Earnings Call Highlights - MarketBeat
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ovid Therapeutics Inc Azioni (OVID) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ALEXANDER MARGARET A. | President and CEO |
Feb 23 '26 |
Sale |
1.45 |
11,656 |
16,901 |
61,750 |
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):